Can a diabetes drug curb obesity in teens with autism?

NCT ID NCT07770152

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial investigates whether semaglutide, a medication used for diabetes and obesity, can help adolescents aged 12-18 with autism spectrum disorder (ASD) and obesity reduce their body mass index (BMI). Participants will receive either semaglutide injections or lifestyle counseling alone for six months. The study will measure changes in BMI, body composition, and metabolic health, while also monitoring safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Semaglutide, a glucagon-like peptide-1 receptor agonist, given as a weekly injection, plus lifestyle management counseling.
What this could lead to
If successful, this could offer a safe and effective weight-management option for adolescents with autism and obesity, potentially improving their metabolic health and quality of life.
What could go wrong
This is a small, early-phase trial, so results may not apply to everyone. Semaglutide can cause side effects like nausea and vomiting, and its long-term effects in this population are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45245, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.